

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

215870Orig1s000

CLINICAL PHARMACOLOGY
REVIEW(S)

Office of Clinical Pharmacology Memo

NDA or BLA Number	215870
Submission Date	04/08/2022
Submission Type	505 (b) (2)
Brand Name	--
Generic Name	Fentanyl Citrate Injection
Dosage Form and Strength	Solution for Injection, 50 mcg (0.05 mg) fentanyl base/mL, available in 50 mL and 100 mL single dose glass vial
Route of Administration	Intravenous
Proposed Indication	• use as an opioid analgesic supplement in general anesthesia. • Administration with a neuroleptic for the induction of anesthesia and as an adjunct in the maintenance of general anesthesia. • use as an anesthetic agent with oxygen in selected high risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures.
Dosage Regimen	Adjunct to General Anesthesia: • Moderate dose of 2 to 20 mcg/kg (0.002 to 0.02 mg/kg) (0.04 to 0.4 mL/kg) for use in more major surgical procedures, in addition to adequate analgesia, may abolish some of the stress response. Administer 25 to 100 mcg (0.025 to 0.1 mg) (0.5 to 2 mL) intravenously as needed when movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. • High dose of 20 to 50 mcg/kg (0.02 to 0.05 mg/kg) (0.4 to 1 mL/kg) for open heart surgery and certain more complicated neurosurgical and orthopedic procedures where surgery is more prolonged, and the stress response to surgery would be detrimental to the well-being of the patient. Maintenance dosage [ranging from 25 mcg (0.025 mg) (0.5 mL) to one half the initial loading dose] as needed based on vital signs indicative of stress or lightening of analgesia. As a General Anesthetic: 50 to 100 mcg/kg (0.05 to 0.1 mg/kg) (1 to 2 mL/kg) may be administered with oxygen and a muscle relaxant. In certain cases, doses up to 150 mcg/kg (0.15 mg/kg) (3 mL/kg) may be necessary to produce this anesthetic effect.
Applicant	Exela Pharma Sciences, LLC
Associated IND	--
OCP Reviewer	Hongwu Shen, Ph.D.
OCP Team leader	Yun Xu, Ph.D.
OCP Division:	Division of Neuropsychiatric Pharmacology (DNP)
OND Division	Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)

Exela Pharma Sciences, LLC submitted a 505(b)(2) NDA application for Fentanyl Citrate Injection 50 mcg base/mL with reference to safety and efficacy established previously in an approved NDA 019101, Fentanyl Citrate Injection preservative free (Listed Drug). The applicant did not conduct any clinical or clinical pharmacology studies and submitted a biowaiver/scientific-bridge request to waive the PK bridging study between the new product and the listed drug in the NDA submission. Refer to the biopharmaceutics session of the CMC review regarding the biowaiver/scientific-bridge request.

(b) (4)

(b) (4)

The Sponsor also relies on the listed drug's labeling language for clinical pharmacology related sections in their proposed labeling. From clinical pharmacology perspective, this NDA submission is acceptable. Labeling negotiation with the applicant is still ongoing as of 12/21/2022.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

HONGWU SHEN
12/22/2022 03:35:46 PM

YUN XU
12/22/2022 04:34:29 PM